Oncology startup Volastra Therapeutics inked a deal with Microsoft to develop unique digital pathology tools for oncology and also announced the New York-based company’s seed funding round was extended from $12 million to $44 million.
The U.S. Food and Drug Administration approved Merck’s anti-PD-1 therapy Keytruda as monotherapy for the first-line treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.
